To evaluate the effectiveness of fast frozen rapid automated immunohistochemistry (FFRA-IHC) in improving tumor classification during intraoperative assessments, highlighting its potential impact on surgical decision-making.
Key Findings:
FFRA-IHC allowed specific classification in 68% of previously unclassifiable tumors, including various tumor types.
All 5 ambiguous resection margins were resolved with FFRA-IHC.
FFRA-IHC potentially altered intraoperative management in approximately 12% of cases.
Turnaround time for FFRA-IHC averaged 21 minutes, with total diagnosis time around 40 minutes.
Interpretation:
FFRA-IHC demonstrates potential to enhance intraoperative decision-making by providing rapid and specific tumor classifications, though its clinical impact needs further validation in broader settings.
Limitations:
Small sample size and single-center design limit generalizability.
Assessment relied on a semiquantitative scoring system not externally validated, affecting reliability.
No evaluation of patient outcomes or long-term clinical impact, limiting conclusions.
Conclusion:
Larger studies with expanded antibody panels are needed to assess the broader applicability and clinical outcomes associated with FFRA-IHC in intraoperative pathology, particularly in translating management changes into measurable surgical and oncologic outcomes.
Creatine's ATP-buffering trick isn't just for biceps. In mice, it juices up dendritic cells' energy supply, sharpening T-cell priming and shrinking tumors on daily injections. Human DCs got the memo too, at least in a dish. Early days, but a fun plot twist for gym-bag chemistry.
